A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
AI’s expansion into the physical world is reshaping what investors choose to back
Updated
March 17, 2026 1:02 AM
Exterior view of the Exchange Square in Central, Hong Kong. PHOTO: UNSPLASH
Artificial intelligence is often discussed in terms of large models trained in distant data centres. Less visible, but increasingly consequential, is the layer of computing that enables machines to interpret and respond to the physical world in real-time. As AI systems move from abstract software into vehicles, cameras and factory equipment, the chips that power on-device decision-making are becoming strategic assets in their own right.
It is within this shift that Axera, a Shanghai-based semiconductor company, began trading on the Hong Kong Stock Exchange on February 10 under the ticker symbol 00600.HK. The company priced its shares at HK$28.2, debuting with a market capitalization of approximately HK$16.6 billion. Its listing marks the first time a Chinese company focused primarily on AI perception and edge inference chips has gone public in the city — a milestone that underscores growing investor interest in the hardware layer of artificial intelligence.
The listing comes at a time when demand for flexible, on-device intelligence is expanding. As manufacturers, automakers and infrastructure operators integrate AI into physical systems, the need for specialized processors capable of handling visual and sensor data efficiently has grown. At the same time, China’s domestic semiconductor industry has faced increasing pressure to build local capabilities across the chip value chain. Companies such as Axera sit at the intersection of these dynamics, serving both commercial markets and broader industrial policy priorities.
For Hong Kong, the debut adds to a cohort of technology companies seeking public capital to scale hardware-intensive businesses. Unlike software firms, semiconductor designers operate in a capital-intensive environment shaped by supply chains, fabrication partnerships and rapid product cycles. Their presence on the exchange reflects a maturing investor appetite for AI infrastructure, not just consumer-facing applications.
Axera’s early backer, Qiming Venture Partners, led the company’s pre-A financing round in 2020 and continued to participate in subsequent rounds. Prior to the IPO, it held more than 6 percent of the company, making it the second-largest institutional investor. The public offering provides liquidity for early investors and new funding for a company operating in a highly competitive and technologically demanding sector.
Axera’s market debut does not resolve the competitive challenges of the semiconductor industry, where innovation cycles are short and global competition is intense. But it does signal that investors are placing tangible value on the hardware, enabling AI’s expansion beyond the cloud. In that sense, the listing represents more than a corporate milestone; it reflects a broader transition in how artificial intelligence is built, deployed and financed — moving steadily from software abstraction toward the silicon that makes real-world autonomy possible.